Clinical trials: Immunologic Deficiency Syndrome
Human Immunodeficiency Virus
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
This study aims to describe the proportion of participants with non-occupational post-exposure prophylaxis (NPEP) failure, defined as NPEP non-completion (including loss to follow-up) at week 4 or primary HIV infection at week 4…
- Trial name
- dPEP (NCT02211690)
- Testing
- dolutegravir 50 mg (one tablet daily), emtricitabine-tenofovir 300/200 mg (one tablet daily)
- Where
- 5 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Andrew Carr
Hiv
Resilient HIV Implementation Science With SGM Youths Using Evidence
The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a…
- Trial name
- RISE (NCT06350682)
- Testing
- HealthMPowerment (HMP)
- Where
- 3 sites in Nigeria, Zambia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HIV/AIDS
Navigating Insurance Coverage Expansion (NICE)
The purpose of this research is to measure the effectiveness of an in-person assistance intervention on successful insurance enrollment, types of insurance coverage, rates of linkage to and retention in HIV-related health care…
- Trial name
- NICE (NCT04263441)
- Testing
- NICE Intervention
- Where
- 3 sites in United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Puerperal Sepsis
Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women
Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than…
- Trial name
- NCT00343317
- Where
- South Africa
- Volunteers
- 1,372 people, healthy volunteers welcome
- Sponsor
- University of KwaZulu
HIV Infections
Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials
AS PER AMENDMENT 10/24/96: To develop a domain/construct-driven neuropsychological and neurological battery. Scaling of instruments to allow measurement of functions from infancy to early adulthood; establish reliability and…
- Trial name
- NCT00000759
- Where
- United States
- Volunteers
- 675 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
HIV Infections
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
To evaluate the safety, tolerability and immunogenicity in humans of the APL-400-047 vaccine when administered intramuscularly by needle and syringe at 1 of 3 doses or by Biojector at the intermediate dose.
- Trial name
- NCT00001088
- Testing
- APL 400-047, Bupivacaine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis B
Hepatitis B Vaccination in HIV-infected Persons
In this study we compare the efficacy of two different HBV-vaccination schedules in HIV-infected persons concerning immune response and compliance. Short schedule: t=0,1,3 weeks and standard schedule: t=0,1,6 months.
- Trial name
- NCT00230061
- Testing
- HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
Vitamin D Deficiency, HIV Infections
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients
The purpose of this study is to determine the effect of normalization of vitamin D levels on bone density, immune and adipocyte function in HIV1-seropositive patients.
- Trial name
- NCT00306410
- Testing
- colecalciferol
- Where
- Netherlands
- Volunteers
- 85 people
- Sponsor
- Radboud University Medical Center
Infection, Human Immunodeficiency Virus, HIV Infections
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years…
- Trial name
- NCT00071760
- Testing
- GW433908, ritonavir
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- ViiV Healthcare
HIV Infections, Drug Use
Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial
The purpose of this study is to compare two implementation approaches [Standard Approach (SA) vs. Tailored Approach (TA)] for scaling-up the evidence-based systems navigation and psychosocial counseling integrated intervention…
- Trial name
- SNaPR01 (NCT03952520)
- Testing
- Standard Approach (SA), Tailored Approach (TA)
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infection
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
- Trial name
- NCT01262846
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Pennsylvania
Cervical Cancer, HIV/AIDS
Cervical Cancer Screening in Cameroon
Human immunodeficiency virus-infected (HIV[+]) women have a several-fold increased risk of invasive cervical cancer (ICC) as well as increased risk of cervical pre-cancer.
- Trial name
- NCT04401670
- Testing
- HPV screening and triage tests, HPV self-sampling
- Where
- Cameroon
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Lymphoma, Nonneoplastic Condition
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00822120
- Testing
- bleomycin sulfate, filgrastim, ABVD regimen
- Where
- 423 sites in United States
- Volunteers
- 371 people
- Sponsor
- SWOG Cancer Research Network
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection.
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT02109224
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects
Primary: Sequentially determine the effects of three dose combinations of tipranavir (TPV) / ritonavir (RTV) (administered b.i.d.), TPV 1250 mg/RTV 100 mg vs. TPV 750 mg/RTV 100 mg vs.
- Trial name
- NCT02251223
- Testing
- Tipranavir low dose, Tipranavir medium dose, Tipranavir high dose
- Volunteers
- 208 people
- Sponsor
- Boehringer Ingelheim
Malabsorption Syndromes, Granulomatous Enteritis
Plasma Citrulline Concentration in Tropical Enteropathy
Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations.
- Conditions
- Malabsorption Syndromes, Granulomatous Enteritis, Enteritis, HIV Enteropathy
- Trial name
- NCT00816842
- Where
- Zambia
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Severe Combined Immunodeficiency, X-Linked
Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency
Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both cellular and humoral immunity.
- Trial name
- NCT03601286
- Testing
- Lentiviral vector transduced CD34+ cells
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
HIV Infections
A Study of DTC in Patients With AIDS and AIDS Related Complex
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents…
- Trial name
- NCT00002069
- Testing
- Ditiocarb sodium
- Where
- 8 sites in United States
- Sponsor
- Merieux Institute
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
- Trial name
- NCT03934541
- Testing
- MPER-656 Liposome Vaccine
- Where
- 6 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)